Indivior Pharmaceuticals, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on October 29, 2026, reporting third-quarter net revenue of $356 million and net income of $137 million.

Key Highlights

  • Net revenue: $356 million for the three months ended September 30, 2026, compared to $314 million in the same period of 2025.
  • Net income: $137 million for Q3 2026, up from $42 million in Q3 2025.
  • Nine-month net revenue: $1,016 million for the nine months ended September 30, 2026, versus $881 million in the prior-year period.
  • Diluted earnings per share: $1.12 for Q3 2026, compared to $0.33 in Q3 2025.
  • Loss on debt extinguishment: $18 million recorded in the nine months ended September 30, 2026, with no comparable amount in 2025.
  • Shares outstanding: 118,035,272 shares of common stock as of October 9, 2026.
  • Proposed merger: The filing references a pending merger with Supernus Pharmaceuticals, Inc., subject to closing conditions and described in the company's forward-looking statements.

Indivior Reports Higher Revenue and Income for Third Quarter and First Nine Months of 2026

According to the filing, Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) reported net revenue of $356 million for the three months ended September 30, 2026, an increase from $314 million in the comparable quarter of 2025. Gross profit for Q3 2026 was $305 million, compared to $230 million in Q3 2025. Cost of sales declined to $51 million from $83 million year-over-year for the quarter. The company reported operating income of $180 million for Q3 2026, compared to $43 million in Q3 2025.

For the nine months ended September 30, 2026, the filing disclosed net revenue of $1,016 million and net income of $348 million, compared to $881 million and $108 million, respectively, in the prior-year period. Total operating expenses for the nine-month period were $398 million, down from $521 million in 2025. The filing noted a $18 million loss on debt extinguishment recorded during the nine months ended September 30, 2026, with no such loss in the comparable 2025 period. Basic earnings per share for the nine-month period were $2.89, versus $0.87 in the prior year.

As of September 30, 2026, the company's balance sheet reflected cash and cash equivalents of $305 million, up from $195 million at December 31, 2025, and total current assets of $800 million compared to $652 million at year-end 2025. The filing also disclosed a pending merger with Supernus Pharmaceuticals, Inc., noting that forward-looking statements regarding the transaction are the company's own and subject to the cautionary language included in the report.

What Was Disclosed

Indivior Pharmaceuticals, Inc. filed its quarterly report for the period ended September 30, 2026, disclosing financial results including net revenue of $356 million and net income of $137 million for Q3 2026, along with balance sheet data and information on a pending merger with Supernus Pharmaceuticals, Inc.